Skip to Content

Join the 'Naltrexone' group to help and get support from people like you.

Naltrexone News

5 Diet Drugs: Which Ones Work?

Posted 14 Jun 2016 by Drugs.com

TUESDAY, June 14, 2016 – Any of the prescription weight-loss drugs on the market can help obese people shed pounds, although some seem more effective than others, a new study finds. Currently, five drugs are approved in the United States for managing obesity. But little has been known about how they stack up against one another, said Dr. Siddharth Singh, the lead researcher on the new study. The findings – based on more than 29,000 people in total – show all five drugs can work. But people on certain drugs tended to be more successful, at least over one year. Specifically, people using Qsymia (phentermine-topiramate) or Victoza (liraglutide) had the highest odds of shedding at least 5 percent of their initial weight. Those taking Xenical (orlistat) had the lowest odds. However, there is no single drug that's "best" for everyone, stressed Singh, an assistant clinical professor at the ... Read more

Related support groups: Obesity, Wellbutrin, Phentermine, Bupropion, Weight Loss, Contrave, Belviq, Wellbutrin XL, Victoza, Adipex-P, Wellbutrin SR, Qsymia, Xenical, Naltrexone, Orlistat, Saxenda, Alli, Zyban, Vivitrol, Liraglutide

3 in 10 Americans Have Drinking Problem at Some Point in Their Lives

Posted 3 Jun 2015 by Drugs.com

WEDNESDAY, June 3, 2015 – Nearly 30 percent of Americans have a problem with alcohol at some point in their lives, ranging from binge drinking to full-blown alcoholism, but less than 20 percent are ever treated, a new study found. Alcohol use disorders are among the most common mental health problems worldwide and result in disability, illness and death, researchers from the U.S. National Institute on Alcohol Abuse and Alcoholism (NIAAA) said. "The problem of alcohol abuse is bigger than people thought," said NIAAA Director George Koob. "Alcohol disorders cost the United States $224 billion a year. "Seventy percent of Americans drink and most don't have a problem, but there is a significant group that do have a problem," he added. One of the biggest concerns, Koob said, is that less than 20 percent of those who have a drinking problem get help. Koob thinks people avoid treatment for a ... Read more

Related support groups: Contrave, Alcohol Dependence, Alcohol Withdrawal, Naltrexone, Campral, Vivitrol, Alcoholism, Hangover, Embeda, Revia, Acamprosate, Bupropion/naltrexone, Morphine/naltrexone, Campral EC, Depade, Acute Alcohol Intoxication

FDA Approves New Obesity Drug Contrave

Posted 12 Sep 2014 by Drugs.com

THURSDAY, Sept. 11, 2014 – The U.S. Food and Drug Administration's approval of a new weight-loss drug on Wednesday marks the third time the agency has given its blessing to a new diet medication since 2012. Called Contrave, the medicine is a combination of two approved drugs: naltrexone, which treats alcohol and drug addiction, and bupropion, which treats depression and seasonal affective disorder and is used to help smokers quit. The agency said in a news release that Contrave can be used by obese adults and by overweight adults who have at least one other weight-related condition or illness, such as high blood pressure or type 2 diabetes. According to the U.S. Centers for Disease Control and Prevention, more than one-third of adults in the United States are obese, the FDA said in its news release. "Obesity continues to be a major public health concern," said Dr. Jean-Marc Guettier, ... Read more

Related support groups: Obesity, Bupropion, Naltrexone

Novel Weight-Loss Drug Contrave Is Approved

Posted 12 Sep 2014 by Drugs.com

THURSDAY, Sept. 11, 2014 – A new weight-loss medication for the overweight and obese has been approved by the U.S. Food and Drug Adminstration. Contrave is a combination of two already-approved drugs, naltrexone and bupropion, in extended-release form. The former is approved to treat alcohol or opioid dependence, while the latter is approved for depression, seasonal affective disorder and as a smoking-cessation aid. The drug is approved for use in people with a body-mass index (BMI) of 30 or higher, which is considered obese, the FDA said in a news release. It also is sanctioned for people with a BMI of 27 or higher, which is considered overweight, who also have at least one weight-related chronic health condition. Such a condition would include high blood pressure, high cholesterol or type 2 diabetes. More than one-third of adults in the United States are obese, the FDA said, citing ... Read more

Related support groups: Obesity, Bupropion, Naltrexone

FDA Approves Contrave (bupropion/naltrexone) for Weight Management

Posted 12 Sep 2014 by Drugs.com

September 10, 2014 – The U.S. Food and Drug Administration today approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia). BMI, which measures body fat based on an individual’s weight and height, is used to define the obesity and overweight categories. According to the Centers for Disease Control and Prevention, more than one-third of adults in the United States are obese. “Obesity continues to be a major public health concern,” said Jean-Marc Guett ... Read more

Related support groups: Obesity, Bupropion, Naltrexone

Drug May Help Women Who Quit Smoking Avoid Weight Gain

Posted 27 Dec 2012 by Drugs.com

THURSDAY, Dec. 27 – Taking a pill called naltrexone (ReVia) when they stop smoking could help women keep dreaded weight gain at bay, according to new research. Researchers analyzed two earlier studies that compared the quit rates and weight gain among heavy smokers who received either naltrexone – a drug used to treat addiction – or an inactive placebo, along with a nicotine patch and weekly counseling while trying to quit smoking. Although the groups taking naltrexone had higher quit rates at the end of four- and six-week treatment courses, participants who took the drug were no more likely to remain abstinent after 12 months. But women who took naltrexone gained significantly less weight six and 12 months after they quit smoking than women who received the placebo, according to the study, published in the December issue of Biological Psychiatry. However, this difference was not ... Read more

Related support groups: Smoking Cessation, Naltrexone, Vivitrol, Revia, Depade

New Diet Pill Wins FDA Panel's Backing

Posted 8 Dec 2010 by Drugs.com

TUESDAY, Dec. 7 – An expert advisory panel recommended on Tuesday that Contrave, a new weight-loss pill that combines an antidepressant with an anti-addiction medication, be approved by the U.S. Food and Drug Administration. The 13-7 vote in favor of Contrave came amid agency concerns that the drug might raise blood pressure in some patients and increase the risk of heart attacks and strokes among some users, according to the Associated Press. But panelists voted 11-8 earlier in the day that those potential health risks could be studied after Contrave was approved. The FDA does not have to follow the advice of its advisory committees, but it typically does. The agency is expected to make a decision on Contrave by Jan. 31, the wire service reported. Contrave is manufactured by Orexigen Therapeutics Inc. In October, the FDA voted against approving two other weight-loss drugs, Arena ... Read more

Related support groups: Obesity, Bupropion, Naltrexone

FDA Approves Vivitrol to Treat Opioid-dependent Patients

Posted 13 Oct 2010 by Drugs.com

ROCKVILLE, Md., Oct. 12, 2010--The U.S. Food and Drug Administration today approved Vivitrol to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment. Vivitrol is an extended-release formulation of naltrexone administered by intramuscular injection once a month. Naltrexone works to block opioid receptors in the brain. It blocks the effects of drugs like morphine, heroin, and other opioids. It was approved to treat alcohol dependence in 2006. "Addiction is a serious problem in this country, and can have devastating effects on individuals who are drug-dependent, and on their family members and society," said Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research. "This drug approval represents a significant advancement in addiction treatment." The safety and efficacy of Vivitrol were studied for six months, ... Read more

Related support groups: Opiate Dependence, Naltrexone, Vivitrol

Combination Treatment May Help Depressed Alcoholics

Posted 15 Mar 2010 by Drugs.com

MONDAY, March 15 – Combined treatment with the antidepressant Zoloft (sertraline) and the alcoholism drug naltrexone improves the likelihood that people with both major depression and alcohol dependence will be able to stop drinking, U.S. researchers report. Their 14-week study of 170 patients found that 54 percent of those who received the combined treatment were able to stop drinking, compared with 21 to 28 percent for patients who received a placebo, Zoloft only, or naltrexone only. The patients who received the combined treatment also went for a longer period of time before they started drinking again – 61 days compared with 15 days for patients in the other groups. The findings may prove an important advance in the treatment of patients with alcohol dependence and depression, said the University of Pennsylvania researchers. "When depression and alcohol dependence occur together, ... Read more

Related support groups: Zoloft, Alcohol Dependence, Naltrexone, Vivitrol, Alcoholism, Revia

Addiction Meds May Help Gamblers

Posted 10 Dec 2009 by Drugs.com

THURSDAY, Dec. 10 – Drugs used to treat substance addictions could prove effective in treating pathological gambling, U.S. researchers say. They tested medications designed to decrease urges and increase inhibitions in two groups of male and female pathological gamblers: those driven by urge (they gamble when the desire becomes too strong to control) and those who don't have normal inhibition of impulsive behaviors (they're unable to control the desire to gamble even when the urges are minimal or nonexistent). The first group – those driven by urge – responded well to medications that block the brain opioid system (such as naltrexone) or certain receptors for the neurotransmitter glutamate (such as memantine). Gamblers with a family history of the problem responded especially well to the opioid blocker, the study found. The second group – those unable to control any impulse to ... Read more

Related support groups: Namenda, Naltrexone, Vivitrol, Memantine, Revia

Ask a Question

Further Information

Related Condition Support Groups

Alcohol Dependence, Fibromyalgia, Opiate Dependence, Trichotillomania, Smoking Cessation

Related Drug Support Groups

Vivitrol, Revia, Depade

Naltrexone Patient Information at Drugs.com